
What is claimed is:

1. A compound having a structure represented by formula I:



(I), or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

X_1 is N, CH, CCl, CF, or CCN;

X_2 is N or CR_4;

R_4 is H, (C_1-C_4)alkyl, halo, OH, NH_2, (C_1-C_4)alkoxy, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, (C_2-C_4)alkenyl, (C_2-C_4)alkynyl, NO_2, CN, NH(C_1-C_4)alkyl, or N(C_1-C_4 alkyl)$_2$;

R_1 is H, OH, or halo;



R_2 is H, OH, or halo;

R_3 is H, halo, or CN;

Y is CH_2, NH, or O;

Z is CH_2, NH, S, or O;

n is 0, 1, or 2;

A is , , , , or ;

X_3 is CH or N;

R_5 is H, (C_1-C_6)alkyl, (C_1-C_6) hydroxyalkyl, (C_1-C_6) aminoalkyl, (C_3-C_6)carbocyclyl, 4- to 7-membered heterocyclyl, (C_1-C_6)alkyl-(C_3-C_7)carbocyclyl, or (C_3-C_7)carbocyclyl-4- to 7-membered heterocyclyl; wherein said alkyl, carbocyclyl, or heterocyclyl is further optionally substituted by one or more, identical or different R_{13} groups, wherein R_{13} is (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo, NH_2, OH, (C_1-C_6)haloalkyl, NH(C_1-C_6)alkyl, or N((C_1-C_6)alkyl)$_2$, (C_3-C_6)carbocyclyl, 4- to 7-membered heterocyclyl, or

R_5 is –L-Y_1-Z_1, wherein

L is absent or (C_1-C_5)alkylene optionally substituted by one or more substituents selected from (C_1-C_2)alkyl and oxo;

Y_1 is absent, O, S, S(O), S(O)$_2$, NR', C(O), C(O)O, OC(O), C(O)N(R'), N(R')C(O), N(R')C(O)N(R'), N(R')C(O)O, OC(O)N(R'), S(O)$_2$N(R'), or N(R')S(O)$_2$;

each R' is independently H or (C_1-C_4)alkyl;

Z_1 is H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_{10})carbocyclyl, or 3- to 10-membered heterocyclyl, wherein Z_1 is optionally substituted by one or more substituents independently selected from (C_1-C_4)alkyl, halo, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, NH_2, (C_1-C_4)aminoalkyl, CN, OH, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR^rR^s, OR^r, $C(O)R^r$, $C(O)OR^r$, $OC(O)R^r$, $C(O)NR^rR^s$, $N(R^r)C(O)R^r$, $S(O)_{0-2}R^r$, $S(O)_2NR^rR^s$, $N(R^r)SO_2R^r$, $Si(R^r)(R^s)R^t$ and $(CH_2)_{1-3}NR^rR^s$; wherein R^r, R^s, and R^t are each independently H, (C_1-C_6)alkyl, or (C_3-C_6)cycloalkyl; or R^r and R^s together with the nitrogen atom to which they are attached form a 4- to 9-membered heterocyclyl which is optionally substituted by one or more substituents selected from (C_1-C_4)alkyl, halo, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylamino, NH_2, CN, and OH;

R_6 is –$L_1CR_{14}R_{15}R_{16}$, or –CH=CH–R_{16}, wherein

L_1 is absent, O, S, (C_1-C_4)alkylene, -O-(C_1-C_4)alkylene, or -S-(C_1-C_4)alkylene;

R_{14} is H or (C_1-C_4)alkyl;


R_{15} is H or (C_1-C_4)alkyl, or

R_{14} and R_{15} together with the carbon atom to which they are attached form a (C_3-C_5)carbocyclyl, 4- to 7-membered heterocyclyl, or C=O;

R_{16} is $(C_1\text{-}C_6)$alkyl, $–NR_{17}R_{18}$, $–OR_{17}$, $–C(O)R_{17}$, $–C(O)OR_{17}$, $–N(R_{18})C(O)R_{17}$, $–C(O)NR_{17}R_{18}$, $–S(O)–(C_1\text{-}C_6)$alkyl, $–S(O)_2–(C_1\text{-}C_6)$alkyl, $–P(O)–(C_1\text{-}C_6$ alkyl$)_2$, $–C(NH)NH_2$, $–(C_1\text{-}C_4)$alkyl$–NR_{18}C(O)R_{17}$, or 4- to 7-membered heterocyclyl, wherein

R_{17} is H, 3- to 6-membered heterocyclyl, or $(C_1\text{-}C_4)$alkyl optionally substituted by one or more, identical or different groups selected from OH, Cl, F, CF_3, $N(C_1\text{-}C_4$ alkyl$)_2$, $(C_3\text{-}C_6)$carbocyclyl, 3- to 6-membered heterocyclyl, $(C_2\text{-}C_4)$alkenyl, and $(C_2\text{-}C_4)$alkynyl;

R_{18} is H or $(C_1\text{-}C_4)$alkyl;

R_7 is H, methyl, $–(CH_2)_{1\text{-}3}W_1W_2$, or 

, wherein

W_1 is $CR_{19}R_{19'}$ or C(O);

R_{19} and $R_{19'}$ are independently H, $(C_1\text{-}C_2)$alkyl, F, OH, CN, NO_2, $(C_1\text{-}C_2)$alkoxy, $(C_1\text{-}C_2)$haloalkyl, $(C_1\text{-}C_2)$haloalkoxy, NH_2, $NH(C_1\text{-}C_2)$alkyl, or $N(C_1\text{-}C_2$ alkyl$)_2$, or

R_{19} and $R_{19'}$ together with the carbon atom to which they are attached form C(O), $(C_3\text{-}C_6)$carbocyclyl or 3- to 6-membered heterocyclyl, which is optionally substituted by one or more substituents independently selected from $(C_1\text{-}C_2)$alkyl, halo, $(C_1\text{-}C_2)$haloalkyl, $(C_1\text{-}C_2)$haloalkoxy, $(C_1\text{-}C_2)$alkoxy, $(C_1\text{-}C_2)$alkylamino, NH_2, CN, and OH;

W_2 is CN, OH, 5- or 6-membered heteroaryl, phenyl, $C(O)\text{-}(C_1\text{-}C_2)$alkyl, $S(O)_2\text{-}(C_1\text{-}C_2)$alkyl, $S(O)(NH)\text{-}(C_1\text{-}C_2)$alkyl, $C(O)OCH_3$, $C(O)NHCH_3$, $CR_{20}R_{21}R_{22}$, NH_2, $NH(C_1\text{-}C_2)$alkyl, or $N(C_1\text{-}C_2$ alkyl$)_2$, wherein

R_{20} is H, $(C_1\text{-}C_2)$alkyl, F, Cl, Br, OH, NH_2, CN, NO_2, $(C_1\text{-}C_2)$alkoxy, $(C_1\text{-}C_2)$haloalkyl, or $(C_1\text{-}C_2)$haloalkoxy;

R_{21} is H, $(C_1\text{-}C_2)$alkyl, F, Cl, Br, OH, CN, NO_2, $(C_1\text{-}C_2)$alkoxy, $(C_1\text{-}C_2)$haloalkyl, $(C_1\text{-}C_2)$haloalkoxy, or $–Y_2\text{-}L_2\text{-}Z_2$, wherein

Y_2 is absent, O, S, S(O), $S(O)_2$, NR', C(O), C(O)O, OC(O), C(O)N(R'), N(R')C(O), $S(O)_2N(R')$, or $N(R')SO_2$;

L_2 is absent or $(C_1\text{-}C_2)$alkylene;

Z_2 is H, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl, phenyl, $(C_3\text{-}C_6)$carbocyclyl, or 4- to 6-membered heterocyclyl, wherein Z_2 is optionally substituted by one or more substituents independently selected from $(C_1\text{-}C_4)$alkyl, halo, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}$

C_4)haloalkoxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylamino, NH_2, CN, OH, C(O)R', C(O)OR', OC(O)R', C(O)NR'R', and N(R')C(O)R', wherein each R' is independently H or (C_1-C_4)alkyl;

or R_{20} and R_{21} together with the carbon atom to which they are attached form (C_3-C_6)carbocyclyl or 3- to 6-membered heterocyclyl, optionally substituted by one or more substituents selected from (C_1-C_2)alkyl, halo, (C_1-C_2)haloalkyl, (C_1-C_2)haloalkoxy, (C_1-C_2)alkoxy, (C_1-C_2)alkylamino, NH_2, CN, and OH;

R_{22} is (C_1-C_2)alkyl, -C(O)OR'', OR'', -C(O)NR'', NR''R'', phenyl, or 5-membered heteroaryl, wherein each R'' is independently H or (C_1-C_2)alkyl;

A" is (C_4-C_6)carbocyclyl or 4- to 6-membered heterocyclyl, optionally substituted with one or more substituents independently selected from (C_1-C_2)alkyl, halo, OH, oxo, CN, and (C_1-C_2)alkoxy;

W_3 is NR_{23} or $CR_{24}R_{24'}$, wherein

R_{23} is H, (C_1-C_2)alkyl, (C_1-C_4)haloalkyl, (C_1-C_4)hydroxyalkyl, -C(O)CH_3, or –C(O)O-(C_1-C_4)alkyl;

R_{24} and $R_{24'}$ are independently H, (C_1-C_2)alkyl, cyclopropyl, F, Cl, Br, OH, NH_2, CN, NO_2, (C_1-C_2)haloalkyl, (C_1-C_2)haloalkoxy, (C_1-C_2)alkoxy, -C(O)OR'', NR''R'', phenyl, or 5-membered heteroaryl;

R_8 is H, (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_4)haloalkyl, or CN, wherein said alkyl or cycloalkyl is optionally substituted by one or more substituents selected from (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, OH, (C_1-C_2)alkoxy, NH_2, NH(C_1-C_2)alkyl, N((C_1-C_2)alkyl)$_2$, (C_1-C_2)aminoalkyl, and halo;

R_8' is H, (C_1-C_4)alkyl, CN, (C_1-C_4)haloalkyl, or –Y_3-L_3-Z_3, wherein

Y_3 is absent, C(O)O, or C(O)N(R'');

L_3 is absent or (C_1-C_2)alkylene;

Z_3 is H, (C_1-C_6)alkyl, phenyl, (C_3-C_6)cycloalkyl, or 4- to 6-membered heterocyclyl, wherein Z_3 is optionally substituted by one or more substituents independently selected from (C_1-C_2)alkyl, halo, (C_1-C_2)haloalkyl, (C_1-C_2)haloalkoxy, (C_1-C_2)alkoxy, NH_2, NO_2, CN, and OH, or

R_8 and R_8', together with the carbon atom to which they are attached, form a (C_4-C_6)carbocyclyl, or 4- to 6-membered heterocyclyl;

A' is a 6- or 7-membered heterocyclyl, which in addition to R_8 and R_8', is optionally further substituted by one more substituents independently selected from oxo, $(C_1$-$C_2)$alkyl, cyclopropyl, spiro-cyclopropyl, halo, $(C_1$-$C_2)$haloalkyl, $(C_1$-$C_2)$haloalkoxy, $(C_1$-$C_2)$alkoxy, NH_2, CN, and OH;

X_4 is CR_{25} or N, wherein

R_{25} is H, F, Cl, or methyl;

R_9 is H, $(C_1$-$C_2)$alkyl, $(C_3$-$C_4)$cycloalkyl, $(C_1$-$C_2)$haloalkyl, CN, $(C_2$-$C_4)$alkenyl, or $(C_2$-$C_4)$alkynyl;

R_9' is $(C_1$-$C_4)$alkyl, CN, $(C_1$-$C_4)$haloalkyl, or $-Y_4$-L_4-Z_4, wherein

Y_4 is absent, C(O), C(O)O, OC(O), C(O)N(R''), or $S(O)_2N(R'')$;

L_4 is absent or $(C_1$-$C_2)$alkylene optionally substituted by one or more substituents selected from $(C_1$-$C_2)$alkyl and oxo;

Z_4 is H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_4)$alkenyl, $(C_2$-$C_4)$alkynyl, phenyl, $(C_3$-$C_6)$carbocyclyl, $(C_3$-$C_6)$cycloalkenyl, or 4- to 6-membered heterocyclyl, wherein Z_4 is optionally substituted by one or more substituents independently selected from oxo, $(C_1$-$C_4)$alkyl, $(C_3$-$C_6)$cycloalkyl, halo, $(C_1$-$C_4)$haloalkyl, $(C_1$-$C_4)$haloalkoxy, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkylamino, NH_2, NO_2, CN, OH, $C(O)R^u$, $C(O)OR^u$, $OC(O)R^u$, $C(O)NR^uR^u$, and $N(R^u)C(O)R^u$, wherein each R^u is independently H, $(C_1$-$C_4)$alkyl, $(C_3$-$C_6)$cycloalkyl, or

Z_4 is $-Q$-L_5-W_4, wherein

Q is absent, O, NH, or $N(C_1$-$C_2)$alkyl;

L_5 is absent or $(C_1$-$C_2)$alkylene optionally substituted by one or more substituents selected from oxo and $(C_1$-$C_2)$alkyl;

W_4 is $(C_1$-$C_4)$alkyl, phenyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkenyl, or 5- or 6-membered heterocyclyl, wherein W_4 is optionally substituted by one or more substituents independently selected from $(C_1$-$C_4)$alkyl, halo, $(C_1$-$C_4)$haloalkyl, $(C_1$-$C_4)$haloalkoxy, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkylamino, NH_2, NO_2, CN, or OH; or

R_9 and R_9', together with the carbon atom to which they are attached, for a $(C_3$-$C_{10})$carbocyclyl or a 4- to 10-membered heterocyclyl, which is optionally substituted by one or more substituents independently selected from oxo, $(C_1$-$C_2)$alkyl, halo, $(C_1$-$C_2)$haloalkyl, $(C_1$-$C_2)$haloalkoxy, $(C_1$-$C_2)$alkoxy, $(C_1$-$C_2)$alkylamino, NH_2, NO_2, CN, or OH; or the $(C_3$-$C_{10})$carbocyclyl or 4- to 10-membered heterocyclyl is optionally fused to a 5- or 6-membered heteroaryl or phenyl ring, and

the 5- or 6-membered heteroaryl or phenyl ring is optionally substituted by $(C_1$-$C_2)$alkyl, halo, $(C_1$-$C_2)$haloalkyl, $(C_1$-$C_2)$haloalkoxy, $(C_1$-$C_2)$alkoxy, $(C_1$-$C_2)$alkylamino, NH_2, NO_2, CN, or OH;

R_9'' is H, $(C_1$-$C_4)$alkyl, $(C_1$-$C_2)$haloalkyl, $(C_1$-$C_2)$alkoxy, $(C_1$-$C_2)$haloalkoxy, CN, NO_2, acetylenyl, phenyl, or 5- or 6-membered heteroaryl, wherein said alkyl, phenyl, or heteroaryl is optionally substituted by one or more substituents independently selected from halo, OH, and NH_2;

X_5 is a absent, $(C_3$-$C_6)$carbocyclyl, $(C_3$-$C_6)$carbocyclyl(C=O), or SO_2;

R_{10} and R_{10}' are each independently H, $(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$hydroxyalkyl, $(C_1$-$C_3)$aminoalkyl, or

R_{10} and R_{10}', together with the same carbon atom to which they are attached, form $(C_3$-$C_6)$carbocyclyl or 4- to 6-membered heterocyclyl, wherein said alkyl, hydroxyalkyl, aminoalkyl, carbocyclyl, or heterocyclyl is optionally substituted by one or more, identical or different R_{10a} groups, wherein R_{10a} is $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkyl-$(C_1$-$C_3)$alkoxy, halo, NH_2, OH, $(C_1$-$C_6)$haloalkyl, NH-$(C_1$-$C_6)$alkyl, N$((C_1$-$C_6)$alkyl$)_2$, $(C_3$-$C_6)$carbocyclyl, 4- to 6-membered heterocyclyl, or

R_{10}' and R_{11}', together with the carbon atoms to which they are attached, form $(C_3$-$C_6)$carbocyclyl or 4- to 6-membered heterocyclyl;

R_{11} and R_{11}' are each independently H, $(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$hydroxyalkyl, $(C_1$-$C_3)$aminoalkyl, or

R_{11} and R_{11}', together with the same carbon atom to which they are attached, form C=O, $(C_3$-$C_6)$carbocyclyl, or 4- to 6-membered heterocyclyl, wherein said carbocyclyl or heterocyclyl is optionally substituted by one or more, identical or different R_{11a} groups, wherein each R_{11a} is independently $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkyl-$(C_1$-$C_3)$alkoxy, halo, NH_2, OH, $(C_1$-$C_6)$haloalkyl, NH-$(C_1$-$C_6)$alkyl, N$((C_1$-$C_6)$alkyl$)_2$, $(C_3$-$C_6)$carbocyclyl, or 4- to 6-membered heterocyclyl, or wherein two R_{11a} groups, together with the same carbon atom to which they are attached, form C=O;

R_{12} is H, OH, NH-$(C_1$-$C_6)$alkyl, NH-$(C_1$-$C_6)$hydroxyalkyl, NH-$(C_1$-$C_6)$aminoalkyl, NH-$(C_3$-$C_6)$carbocyclyl, NH-4- to 6-membered heterocyclyl, NH-$(C_1$-$C_6)$alkyl-$(C_3$-$C_6)$carbocyclyl, or NH-$(C_1$-$C_6)$alkyl-4- to 6-membered heterocyclyl, wherein said alkyl, hydroxyalkyl, aminoalkyl, carbocyclyl, or heterocyclyl is further optionally substituted by one or more, identical or different R_{12a} groups, wherein each R_{12a} is independently $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkyl-$(C_1$-

C_3)alkoxy, halo, NH_2, OH, (C_1-C_6)haloalkyl, NH-(C_1-C_6)alkyl, N((C_1-C_6)alkyl)$_2$, (C_3-C_6)carbocyclyl, or 4- to 6-membered heterocyclyl;

m is 0, 1, or 2; and

o is 0 or 1.

2. The compound of claim 1, wherein

a) Z is O,

b) Z is CH_2,

c) Y is CH_2,

d) Y is O, or

e) Y is NH.

3. The compound of claim 1, wherein

a) n is 0,

b) n is 1,

c) n is 2,

d) R_1 and R_2 are each H, or



e) R_1 and R_2 are each halo, optionally wherein R_1 and R_2 are each F.

4. The compound of claim 1, wherein

a) X_1 is N,

b) R_3 is halo, optionally wherein R_3 is Cl or F, or

c) X_2 is CH.

5. The compound of claim 1, wherein A is  and the compound of formula (I) has the structure of formula I-1,  (I-1), or a pharmaceutically acceptable salt or stereoisomer thereof.

6. The compound of claim 5, wherein

a) R_5 is methyl,

b) X_3 is CH, or


c) R_6 is $–L_1CR_{14}R_{15}R_{16}$,



optionally wherein

i) L_1 is -O-(C_1)alkylene,

ii) R_{14} and R_{15} together with the same carbon atom to which they are attached form C=O, or

iii) R_{16} is methyl, OH, NH_2, or NHMe.

7. The compound of claim 5, which has the structure of formula I-1a,  (I-1a), or a pharmaceutically acceptable salt or stereoisomer thereof.

8. The compound of claim 1, wherein A is  and the compound of formula (I) has the structure of formula I-2,  (I-2), or a pharmaceutically acceptable salt or stereoisomer thereof.

9. The compound of claim 8, wherein

a) R_5 is methyl,

b) R_7 is $–(CH_2)_2W_1W_2$,

optionally wherein


i) W_1 is $CR_{19}R_{19'}$, or

ii) W_2 is CN, OH, or NH_2,


further optionally wherein R_{19} and $R_{19'}$ are both methyl, or

c) R_7 is H or methyl.


10. The compound of claim 8, which has the structure of formula I-2a, I-2b, or I-2c:



(I-2a),




(I-2b),




(I-2c), or a pharmaceutically acceptable salt or stereoisomer thereof.

11. The compound of claim 1, wherein A is



and the compound of formula (I) has the structure of formula I-3,



(I-3), or a pharmaceutically acceptable salt or stereoisomer thereof.


12. The compound of claim 11, wherein

a) R_5 is methyl,

b) R_8 is (C_3-C_6)cycloalkyl and R_8' is H, or


c) A' is a 7-membered heterocyclyl, wherein the heterocyclyl contains 2 heteroatoms selected from N and O, and which in addition to R_8 and R_8', is optionally further substituted by one more substituents independently selected from oxo, (C_1-C_2)alkyl, cyclopropyl, spiro-cyclopropyl, halo, (C_1-C_2)haloalkyl, (C_1-C_2)alkoxy, NH_2, CN, and OH.


13. The compound of claim 11, which has the structure of formula I-3a,




(I-3a), or a pharmaceutically acceptable salt or stereoisomer thereof.


14. The compound of claim 1, wherein

a) A is  and the compound of formula (I) has the structure of formula I-4,





(I-4), or a pharmaceutically acceptable salt or stereoisomer thereof,

b) A is  and the compound of formula (I) has the structure of formula I-5,



(I-5), or a pharmaceutically acceptable salt or stereoisomer thereof, or

c) A is  and the compound of formula (I) has the structure of formula I-6,



(I-6), or a pharmaceutically acceptable salt or stereoisomer thereof.

15. The compound of claim 14, wherein in c), wherein

a) R_5 is methyl,

b) m is 1,

c) m is 0,

d) X_5 is absent,

e) o is 1,


optionally wherein R_{10} and R_{11} are each H, and R_{10}' and R_{11}', together with the carbon atoms to which they are attached, form cyclobutyl,

f) R_{12} is OH, or


g) o is 0,

optionally wherein R_{12} is H.

16. The compound of claim 14, wherein in c), which has the structure of formula I-6a or I-6b,




(I-6a) or




(I-6b), or a pharmaceutically acceptable salt or stereoisomer thereof.


17. The compound of claim 1, which is:




(1),




(2),




(3),




(4),




(5),




(6),




(7),




(8),




(9),




(10),




(11),




(12),




(13),




(14),




(15),




(16),




(17),




(18-1),




(18-2),




(19-1),




(19-2),




(20),




(21),




(22),




(23),




(24),




(25),




(26),




(27),




(28),




(29),




(30),




(31),




(32),




(33),




(34),




(35),




(36),




(37),




(38),




(39),




(40),




(41),




(42),



(43),



(44),



(45), or a pharmaceutically acceptable salt or stereoisomer thereof.

18. A pharmaceutical composition, comprising the compound or pharmaceutically acceptable salt or stereoisomer of any one of claims 1-17, and a pharmaceutically acceptable carrier.

19. Use of the compound or a pharmaceutically acceptable salt or stereoisomer thereof of any one of claims 1-17, or the pharmaceutical composition of claim 18 in the manufacture of a medicament for treatment of a disease or disorder that involves aberrant B-cell lymphoma 6 (BCL6) activity, optionally wherein the disease or disorder is cancer or an inflammatory disease.

20. The use of claim 20, wherein

a) the cancer is a lymphoid malignancy,

optionally wherein the lymphoid malignancy is peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia/lymphoma (ALL), or cutaneous T-cell lymphoma,

further optionally, wherein the medicament is to be administered with an additional anti-cancer agent,

even further optionally wherein the additional anti-cancer agent is an enhancer of zeste homolog 2 (EZH2) inhibitor, or

b) the inflammatory disease is inflammatory bowel disease, myocarditis, endometriosis, atherosclerosis, an allergic disease, or an autoimmune disease,

optionally wherein the allergic disease is asthma or pollinosis, or

optionally wherein the autoimmune disease is noninfectious meningitis, autoimmune encephalitis, transverse myelitis, or acute disseminated encephalomyelitis.